SCHEMBL1713680

SCHEMBL1713680

CCOC(=O)C(C)=CC1CCN(C(=O)O)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.44
GAA P10253 2/20 0.42
ALDH1A1 P00352 4/20 0.42
L3MBTL1 Q9Y468 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
NOS3 P29474 1/20 0.38
NOS2 P35228 1/20 0.38
THRB P10828 1/20 0.37
ATM Q13315 1/20 0.37
TP53 P04637 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
GLO1 Q04760 1/20 0.35
CHRM1 P11229 1/20 0.35
BRD4 O60885 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21644269 1.00 MAPT (0.44) MAPTGAAALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL28585644 0.84 GLO1 (0.44) MAPTGAAALDH1A1SMN1; SMN2MEN1
SCHEMBL4437414 0.82 HPGD (0.44) MAPTGAAALDH1A1SMN1; SMN2MEN1
SCHEMBL22284199 0.82 HPGD (0.44) MAPTGAAALDH1A1SMN1; SMN2MEN1
SCHEMBL20060955 0.82 HPGD (0.44) MAPTGAAALDH1A1SMN1; SMN2MEN1
SCHEMBL30451740 0.81 MAPT (0.37) MAPTGAAALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL632279 0.80 GLO1 (0.41) MAPTGAAALDH1A1L3MBTL1KMT2A
SCHEMBL25563386 0.80 GLO1 (0.41) MAPTGAAALDH1A1SMN1; SMN2MEN1
SCHEMBL16964559 0.80 CYP2C9 (0.46) MAPTGAAALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL17104593 0.80 CYP2C9 (0.46) MAPTGAAALDH1A1L3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3526203-B1 N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME (US) 2021-09-22 EP disclosed
US-10961215-B2 N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use MERCK SHARP & DOHME CORP. (US) 2021-03-30 US disclosed
US-20200039951-A1 N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME CORP. (US) 2020-02-06 US disclosed
EP-2114935-B1 PIPERIDINE GPCR AGONISTS PROSIDION LTD (GB) 2011-07-20 EP disclosed
EP-2114935-A1 PIPERIDINE GPCR AGONISTS Prosidion Limited (GB) 2009-11-11 EP disclosed
EP-2114933-A1 PIPERIDINE GPCR AGONISTS Prosidion Limited (GB) 2009-11-11 EP disclosed
WO-2008081207-A1 PIPERIDINE GPCR AGONISTS PROSIDION LIMITED (GB) 2008-07-10 WO disclosed
WO-2008081204-A1 PIPERIDINE GPCR AGONISTS PROSIDION LIMITED (GB) 2008-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200039951-A1 N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE NR1H2, NR1H3, NR1H4 MAPT 1298/4885GAA 1405/4885ALDH1A1 736/4885
US-10961215-B2 N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use NR1H2, NR1H3, NR1H4 MAPT 1298/4885GAA 1405/4885ALDH1A1 736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.